The drug pricing saga continues, and this time the victor is Canada. Canadians are now accessing generic semaglutide (the active ingredient in Ozempic) at a fraction of the cost faced by their American neighbours. The British NHS pricing model, long derided by free-market advocates, is being hailed as a triumph. For those of us who track the intersection of fiscal policy and public health, this is a textbook case of regulatory leverage versus market forces.
Let us examine the numbers. In Canada, a month's supply of generic semaglutide retails for roughly CAD 150. Across the border, Americans pay upwards of USD 900 for the same branded product. The difference is staggering, and it is not accidental. Canada, like the UK, employs a single-payer bargaining system that gives the government immense negotiating power. The NHS, for instance, sets a maximum price it will pay for drugs, and manufacturers either accept or lose access to 67 million patients. This is not socialism; it is monopsony power in action.
Meanwhile, the United States operates a fragmented system where insurers, pharmacy benefit managers, and middlemen all take a cut. The result is a pricing structure that bears no relation to production costs. Ozempic's list price in the US has soared by over 50% since 2019, even as manufacturing efficiencies should have reduced costs. This is not market efficiency; it is rent-seeking on a grand scale.
The British model's vindication comes at a critical time. The NHS recently secured a landmark deal with Novo Nordisk, the manufacturer of Ozempic, to cap prices for a new generation of weight-loss drugs. The deal was kept under wraps until now, but sources confirm that the UK will pay around 80% less than the US list price. This is precisely the kind of fiscal discipline that bond markets reward. Gilt yields have remained stable despite rising healthcare spending, because the NHS's bargaining power contains costs.
Critics will argue that price controls stifle innovation. They point to the US as the engine of pharmaceutical R&D. But let us be clear: the US system is a casino, not a laboratory. Drug companies spend twice as much on marketing as on research, and most breakthrough drugs are discovered in publicly funded labs. The argument that high prices drive innovation is a convenient fiction for shareholders.
Capital flight is a related concern. If American drug companies see their profits squeezed by Canadian and British policies, they might relocate. But where would they go? Europe offers large, regulated markets; Asia is growing. The US cannot take its pharmaceutical dominance for granted. The real risk is that American patients will continue to pay the highest prices in the world while subsidising the rest of the globe's access to life-saving drugs.
For investors, this news is a signal. Biotech firms with heavy exposure to US pricing may face headwinds. But companies that have diversified across regulated markets, like Novo Nordisk itself, are better positioned. The market's reaction on Tuesday showed a flight to quality: Novo shares rose 2% while US-focused peers dipped.
In the end, the Canadian victory is a reminder that drug pricing is not a matter of free markets vs. socialism. It is a matter of pragmatic fiscal management. The NHS model, with its emphasis on value-based pricing and bulk purchasing, delivers lower costs without compromising access. As inflation remains stubbornly above target in both the UK and US, every pound or dollar saved on healthcare is a pound or dollar that can be deployed elsewhere. The market should take note.
